115 related articles for article (PubMed ID: 12127917)
1. Low molecular weight heparin: a bridge over troubled water.
Verheugt FW
Eur Heart J; 2002 Aug; 23(15):1144-6. PubMed ID: 12127917
[No Abstract] [Full Text] [Related]
2. Long-term management--the way forward?
Wallentin L
Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I13-7. PubMed ID: 10680039
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparins in acute coronary syndrome.
Creekmore F
S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
[No Abstract] [Full Text] [Related]
4. Management of unstable coronary-artery disease.
Cohen AT
Lancet; 2000 Feb; 355(9203):574. PubMed ID: 10683025
[No Abstract] [Full Text] [Related]
5. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
6. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
7. Acute coronary care and beyond: the expanding role of low-molecular-weight heparin.
Verheugt FW; Chesebro JH
Clin Cardiol; 2001 Mar; 24(3 Suppl):I1-2. PubMed ID: 11286308
[No Abstract] [Full Text] [Related]
8. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
9. [Low molecular weight heparin in unstable angina].
Kher A; Samama MM
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1495-500. PubMed ID: 9092409
[TBL] [Abstract][Full Text] [Related]
10. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
Pineo GF; Hull RD
Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
[TBL] [Abstract][Full Text] [Related]
11. Update on pharmacologic therapy for pulmonary embolism.
Harikrishnan P; Palaniswamy C; Aronow WS
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):159-69. PubMed ID: 24177334
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
13. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
14. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
15. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
Caine GJ; Lip GY
Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
[No Abstract] [Full Text] [Related]
16. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
Douketis JD; Johnson JA; Turpie AG
Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
[TBL] [Abstract][Full Text] [Related]
17. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?].
Panchenko EP
Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
James S; Armstrong P; Califf R; Husted S; Kontny F; Niemminen M; Pfisterer M; Simoons ML; Wallentin L
Eur Heart J; 2002 Oct; 23(19):1538-45. PubMed ID: 12242074
[TBL] [Abstract][Full Text] [Related]
19. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Arjomand H; Cohen M; Ezekowitz MD
J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
Verheugt FW
Haemostasis; 2000; 30 Suppl 2():122-7; discussion 106-7. PubMed ID: 11251355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
